Skip to Content

Ilaris Approval History

Ilaris (canakinumab) is a human anti-interleukin-1β monoclonal antibody for the treatment of Periodic Fever Syndromes (Cryopyrin-Associated Periodic Syndromes, Tumor Necrosis Factor Receptor Associated Periodic Syndrome, Hyperimmunoglobulin D Syndrome/Mevalonate Kinase Deficiency, Familial Mediterranean Fever) and active Systemic Juvenile Idiopathic Arthritis.

Development History and FDA Approval Process for Ilaris

Sep 23, 2016Approval FDA Approves Expanded Indications for Ilaris (canakinumab) for Three Rare Periodic Fever Syndromes
May 10, 2013Approval Ilaris Approved by FDA to Treat Active Systemic Juvenile Idiopathic Arthritis
Aug 29, 2011FDA Requests Additional Clinical Data on Novartis Drug ACZ885 for the Treatment of Gouty Arthritis
Jun 22, 2011FDA Panel Endorses Efficacy but Not Safety of Novartis Drug ACZ885 for Gouty Arthritis; Did Not Support Approval in Proposed Indication
Jun 18, 2009Approval New Biological Therapy Ilaris Approved In US To Treat Children And Adults With CAPS, A Serious Life-Long Auto-Inflammatory Disease

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.